CDK4 and breast carcinoma: Two hundred eighty-eight patients with ER positive HER2 negative advanced breast cancer were treated with CDK4/6 inhibitors in our center from November 2017 to February 2022 (149 pts with ribociclib, 117 with palbociclib, and 22 with abemaciclib; 285 women and three men).